News

ICER Faces New Foe As Patient, Disability Alliance Takes Aims At Reports On Mayzent, Spravato

06.28.19

An article in The Pink Sheet highlighted the Partnership to Improve Patient Care (PIPC)’s involvement with Value Our Health — a new initiative supported by organizations representations patients and people with disabilities. The article highlights Value Our Health’s opposition to the Institute for Clinical and Economic Review’s (ICER) use of the quality-adjusted-life-years (QALY) metric, nothing that the patients groups have long criticized the method as a one-size-fits-all approach to addressing the needs of patients. “It is disappointing that ICER…

Patient Advocates Say ICER Uses Discriminatory Cost Metrics

06.27.19

A coalition of patient advocates, provider groups and drug makers is criticizing the Institute for Clinical and Economic Review for using a metric they say discriminates against people with disabilities and chronic illness. ICER has responded to the criticism by saying it will include alternative, less controversial metrics in its cost-effectiveness reports. The metric at issue is the Quality-Adjusted Life-Year, which is a commonly used standard internationally to determine the cost-effectiveness of medical treatments, including…

Putting Our Guard Down: Engaging Multiple Stakeholders To Define Value In Healthcare

01.28.19

Pharmaceutical companies want to sell pharmaceuticals.  Insurers want to keep per-member-per-month costs below monthly member premiums. Providers want to see their patients get access to care.  Patients want to feel better and live longer. What would happen if multiple representatives from each of these groups were put in a room and asked what they value in terms of health services? Could we get past tensions from multiple perspectives, potential competing interests, or previous transgressions from…

BLOG POST: FORMULARY RESTRICTIONS DEVALUE AND ENDANGER THE LIVES OF DISABLED PEOPLE

10.29.18

As policymakers around the world seek to manage rising drug expenditures, people with disabilities find ourselves increasingly concerned by the potential harms that cost-cutting measures may bring. The growing fight between health care purchasers and drug manufacturers offers yet another instance where people with disabilities and chronic conditions may find themselves caught in the cross-fire. CVS Caremark’s recently announced policy allowing self-insured employers to exclude new drugs from their formularies based on a flawed cost-effectiveness measure has…

FORMULARY RESTRICTIONS DEVALUE AND ENDANGER THE LIVES OF DISABLED PEOPLE

10.29.18

As policymakers around the world seek to manage rising drug expenditures, people with disabilities find ourselves increasingly concerned by the potential harms that cost-cutting measures may bring. The growing fight between health care purchasers and drug manufacturers offers yet another instance where people with disabilities and chronic conditions may find themselves caught in the cross-fire.

SUSAN LINN, EPILEPSY FOUNDATION NEW ENGLAND: DON’T PUT A PRICE CAP ON PEOPLE’S LIVES

10.06.18

When a person is first diagnosed with epilepsy their world is turned upside down. The questions come fast and furious. What does this mean for my life? Will I die from this? Can I pass this along to my children? Why me? Can this disease be managed, and will I still be able to participate in life and all that is important to me? The answer to that last question is critical because everything suddenly…